Lentiviral Vector Manufacturer, Theravectys, Granted a Manufacturing Establishment by the ANSM in Frence

The French National Agency for Medicines and Health Products Safety (ANSM) granted a GMP pharmaceutical establishment, Theravectys, to produce lentiviral vectors for clinical development from phase I through phase III.

The new GMP facility will be used to handle human cells producing himeric antigen receptors (CARs) and T-cell receptor (TCR)-based cell therapies. 

The Theravectys has over 10 years of experience in lentiviral vector-based therapy and has successfully performed the first vaccination trial performed in humans with lentiviral vectors. (read more here from Yahoo News). 

Learn about "Lentiviral Vector-Based Therapy"

Global Compliance Seminar (GCS) provides global and FDA regulatory consulting and training services to the FDA-regulated industry in collaboration with the Regulatory Doctor. The US FDA is an Agency under the US Department of Health and Human Services (DHHS).